Enhancing Multidisciplinary Collaboration to Optimize mCSPC Care

This segment explores how multidisciplinary collaboration enhances care for patients with metastatic castration-sensitive prostate cancer (mCSPC). Panelists discussed how effective coordination between urology, medical oncology, and radiation oncology ensures comprehensive, timely decision-making—whether in academic centers or community practices. In some settings, collaboration occurs through formal tumor boards and joint clinical programs, while others rely on informal but efficient communication via shared electronic medical records, text messaging, and virtual consults. Radiation oncologists play an increasingly vital role, particularly with radioligand and metastasis-directed therapies, as well as monitoring treatment-related toxicities. The discussion underscored that collaboration is not confined to large institutions; even community practices can achieve robust teamwork through consistent communication and mutual trust. Ultimately, the panel emphasized that effective multidisciplinary coordination—formal or informal—streamlines care, reduces delays, and improves patient outcomes by leveraging the expertise of each specialty at every stage of the disease continuum.

Panelists noted that abiraterone, apalutamide, and enzalutamide demonstrate overall survival benefits, while darolutamide primarily delays progression. They discussed side-effect profiles and monitoring needs—highlighting the need for liver function monitoring and steroid co-administration with abiraterone—and emphasized that treatment selection often depends on balancing efficacy, toxicity, and clinician comfort.